Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2008

View Archived Issues

Aileron's Staple Peptide targets a novel interaction site for BAX activation

Pfizer's CP-751871 appears to be safe and well tolerated in phase II breast cancer study

Enhanced antimalarial activity for a newly identified acridone derivative

Single dose of new meningococcal vaccine shows immunological memory in African children

Safety and immunogenicity for a new malaria vaccine, MSP3-LSP, in phase Ib study

Novel antiinfective agents described in recent GSK patent

Cadence presents positive top-line results from phase III Acetavance trial

PharmaMar initiates phase II studies for Irvalec in non-small cell lung cancer

Positive phase II results reported for C-105 in MS-associated cognitive dysfunction

Supernus initiates phase III trial in refractory partial onset epileptic seizures

TopoTarget opens enrollment for first pivotal belinostat trial in PTCL

AkzoNobel to acquire 75/25 majority interest in joint venture with Nippon Kayaku

Nabi enters CRADA with USU and HJF to develop S. aureus vaccine

PTC Therapeutics initiates two clinical trials for PTC-299

Resolvyx commences phase I/II trial for novel resolvin therapeutic RX-10045

Sucampo initiates phase I SPL-017 study for peripheral arterial disease

Antisense completes dosing in mouse and primate toxicology studies of ATL-1103

Auxilium and Pfizer sign agreement to develop and commercialize Xiaflex in Europe

Biopure submits IND to FDA for phase II clinical trial of Hemopure in AML

KAI initiates enrollment in phase IIb study of KAI-9803 in STEMI

Arete Therapeutics reports positive phase I AR-9281 data in healthy volunteers

ARYx Therapeutics reports outcome of ATI-2042 trial in atrial fibrillation

Cytokinetics reports phase IIa CK-1827452 results in ischemic cardiomyopathy

Achillion patent reports new antibacterial agents

Novel monoclonal antibodies targeting IRC85 described in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...